Intra-operative Chemotherapy for Ovarian Cancer
Author Information
Author(s): Guardiola Emmanuel, Delroeux Delphine, Heyd Bruno, Combe Marielle, Lorgis Veronique, Demarchi Martin, Stein Ulrich, Royer Bernard, Chauffert Bruno, Pivot Xavier
Primary Institution: University Hospital Jean Minjoz
Hypothesis
Is intra-operative intra-peritoneal chemotherapy with cisplatin feasible for patients with peritoneal carcinomatosis of ovarian cancer?
Conclusion
The study shows that intra-operative i.p. chemotherapy with cisplatin is feasible after optimal resection of peritoneal tumor nodules.
Supporting Evidence
- No severe toxicity was reported from the intra-operative i.p. chemotherapy.
- No patient died due to complications from surgery or chemotherapy.
- The median duration of surgery was 7 hours and 10 minutes.
- The median hospitalization duration was 3 days in intensive care.
Takeaway
Doctors tested a new way to give chemotherapy during surgery for ovarian cancer, and it worked without causing serious side effects.
Methodology
47 patients with stage III ovarian cancer received standard chemotherapy and underwent surgery with intra-operative i.p. chemotherapy using cisplatin.
Limitations
The study was limited to a small sample size and lacked a control group for comparison.
Participant Demographics
Median age was 59.6 years, with 66% having initial chemotherapy followed by surgery.
Statistical Information
Confidence Interval
[95% CI, 55% to 70%]
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website